BR112014001283A2 - métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício - Google Patents
métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercícioInfo
- Publication number
- BR112014001283A2 BR112014001283A2 BR112014001283A BR112014001283A BR112014001283A2 BR 112014001283 A2 BR112014001283 A2 BR 112014001283A2 BR 112014001283 A BR112014001283 A BR 112014001283A BR 112014001283 A BR112014001283 A BR 112014001283A BR 112014001283 A2 BR112014001283 A2 BR 112014001283A2
- Authority
- BR
- Brazil
- Prior art keywords
- cardiovascular disease
- subject
- exercise therapy
- individual
- therapy
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
abstract methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. these methods include determining a level of soluble st2 in a subject. ----------------------------------------------------------------------------- tradução do resumo resumo patente de invenção: "métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício". a presente invenção refere-se aos métodos de tratamento de um indivíduo que tem uma doença cardiovascular, a seleção de uma terapia para um paciente portador de uma doença cardiovascular, a identificação de um indivíduo com uma doença cardiovascular que irá beneficiar ou não beneficiar da terapia de exercício, determinar se um indivíduo com uma doença cardiovascular deve começar, continuar, não começar, interromper ou evitar a terapia de exercícios, determinar se um indivíduo que tem uma doença cardiovascular deve continuar, interromper ou evitar a terapia de exercício, reduzindo o risco de um resultado adverso (por exemplo, morte) em um indi-víduo que tem uma doença cardiovascular, e predizer a eficácia da terapia de exercício em um indivíduo com uma doença cardiovascular. estes métodos incluem a determinação de um nível de st2 solúvel em um indivíduo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161508923P | 2011-07-18 | 2011-07-18 | |
US201161509359P | 2011-07-19 | 2011-07-19 | |
PCT/US2012/047238 WO2013012945A1 (en) | 2011-07-18 | 2012-07-18 | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014001283A2 true BR112014001283A2 (pt) | 2017-02-21 |
Family
ID=47558450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014001283A BR112014001283A2 (pt) | 2011-07-18 | 2012-07-18 | métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício |
Country Status (13)
Country | Link |
---|---|
US (5) | US8748110B2 (pt) |
EP (2) | EP2734222B1 (pt) |
JP (2) | JP6134316B2 (pt) |
CN (2) | CN103796669B (pt) |
AU (2) | AU2012284039B2 (pt) |
BR (1) | BR112014001283A2 (pt) |
CA (1) | CA2842072A1 (pt) |
DK (1) | DK2734222T3 (pt) |
ES (1) | ES2611403T3 (pt) |
HK (1) | HK1198125A1 (pt) |
MX (1) | MX351428B (pt) |
PL (1) | PL2734222T3 (pt) |
WO (1) | WO2013012945A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
ES2573471T3 (es) | 2002-05-09 | 2016-06-08 | The Brigham And Women's Hospital, Inc. | 1L1RL-1 como un marcador de enfermedades cardiovasculares |
JP5383480B2 (ja) | 2006-04-24 | 2014-01-08 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 致死性の予測および重大な疾患の検出 |
WO2007143295A2 (en) * | 2006-04-27 | 2007-12-13 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
EP2482078B1 (en) | 2006-05-01 | 2016-02-03 | Critical Care Diagnostics, Inc. | Diagnosis of cardiovascular disease |
HUE025058T2 (en) * | 2006-05-02 | 2016-01-28 | Critical Care Diagnostics Inc | Differential diagnosis of pulmonary and cardiovascular disease |
EP3093663B1 (en) | 2008-04-18 | 2018-06-13 | Critical Care Diagnostics, Inc. | Predicting risk of major adverse cardiac events |
EP2556090B1 (en) | 2010-04-09 | 2016-02-24 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
CN106940375B (zh) | 2011-03-17 | 2019-03-08 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
DK2734222T3 (en) | 2011-07-18 | 2017-01-30 | Critical Care Diagnostics Inc | PROCEDURES FOR TREATING CARDIOVASCULAR DISEASES AND PREDICTING THE EFFECTIVENESS OF MOTION THERAPY |
EP3434260A1 (en) | 2012-05-18 | 2019-01-30 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of ventricular tachyarrhythmia event |
WO2014028875A1 (en) | 2012-08-16 | 2014-02-20 | Critical Care Diagnostics, Inc. | Methods for predicting risk of developing hypertension |
SG11201501271TA (en) | 2012-08-21 | 2015-03-30 | Critical Care Diagnostics Inc | Multimarker risk stratification |
CN104017056B (zh) * | 2014-06-27 | 2016-08-17 | 国科戎安生物科技(北京)有限公司 | St2蛋白抑制剂多肽及其应用 |
CN104017057B (zh) * | 2014-06-27 | 2016-08-24 | 榆林市第一医院 | 一种st2蛋白抑制剂多肽及其应用 |
ES2792227T3 (es) | 2014-09-26 | 2020-11-10 | Somalogic Inc | Predicción de evento de riesgo cardiovascular y usos de la misma |
CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
PE20170910A1 (es) | 2014-11-10 | 2017-07-12 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
CN105259353B (zh) * | 2015-10-15 | 2017-03-22 | 北京市心肺血管疾病研究所 | 一种主动脉瘤和/或主动脉夹层患者血液中可溶性st2的检测试剂盒及检测方法 |
WO2017179693A1 (ja) * | 2016-04-15 | 2017-10-19 | オムロン株式会社 | 生体情報分析装置、生体情報分析システム、プログラム、及び、生体情報分析方法 |
BR112018071395A2 (pt) * | 2016-04-18 | 2019-02-05 | Centre Dinvestigation Clinique Plurithematique Pierre Drouin Inserm Chu De Nancy Inst Lorrain Du Coe | métodos de identificação de pacientes, método de previsão do risco de progressão para lvh, método de diferenciação em pacientes, métodos de previsão se pacientes se encontram com risco de progressão para lvh e uso |
CN108982871B (zh) * | 2018-07-19 | 2021-09-24 | 北京市心肺血管疾病研究所 | 血清sST2在小儿扩张型心肌病预后中的应用 |
CN115605507A (zh) | 2020-03-13 | 2023-01-13 | 基因泰克公司(Us) | 抗白介素-33抗体及其用途 |
RU2741195C1 (ru) * | 2020-03-27 | 2021-01-22 | Государственное бюджетное учреждение здравоохранения Нижегородской области "Нижегородская областная клиническая больница им. Н.А. Семашко" | Способ прогнозирования ургентных сердечно-сосудистых осложнений при остром коронарном синдроме у больных с онкологическим заболеванием в анамнезе |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4302386A (en) | 1978-08-25 | 1981-11-24 | The Ohio State University | Antigenic modification of polypeptides |
US4105776A (en) | 1976-06-21 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
JPS533020A (en) | 1976-06-29 | 1978-01-12 | Matsushita Electric Ind Co Ltd | Static picture reception unit |
US4316906A (en) | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
US4508729A (en) | 1979-12-07 | 1985-04-02 | Adir | Substituted iminodiacids, their preparation and pharmaceutical compositions containing them |
US4344949A (en) | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
ZA817261B (en) | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
US4337201A (en) | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
US4410520A (en) | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
GB2128984B (en) | 1982-05-12 | 1985-05-22 | Hoffmann La Roche | Diaza-bicyclic compounds |
JPS5911218U (ja) | 1982-07-14 | 1984-01-24 | 松下電器産業株式会社 | 燃焼器 |
US4816463A (en) | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
US4772684A (en) | 1987-01-20 | 1988-09-20 | Triton Biosciences, Inc. | Peptides affecting blood pressure regulation |
US5081127A (en) | 1988-01-07 | 1992-01-14 | E. I. Du Pont De Nemours And Company | Substituted 1,2,3-triazole angiotensin II antagonists |
US5064825A (en) | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
US5073566A (en) | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
US5085992A (en) | 1990-07-19 | 1992-02-04 | Merck & Co., Inc. | Microbial transformation process for antihypertensive products |
US5087634A (en) | 1990-10-31 | 1992-02-11 | G. D. Searle & Co. | N-substituted imidazol-2-one compounds for treatment of circulatory disorders |
US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
GB2372114A (en) * | 2001-02-07 | 2002-08-14 | Cardionetics Ltd | A computerised physical exercise program for rehabilitating cardiac health patients together with remote monitoring |
ES2573471T3 (es) | 2002-05-09 | 2016-06-08 | The Brigham And Women's Hospital, Inc. | 1L1RL-1 como un marcador de enfermedades cardiovasculares |
JP5383480B2 (ja) | 2006-04-24 | 2014-01-08 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 致死性の予測および重大な疾患の検出 |
WO2007143295A2 (en) | 2006-04-27 | 2007-12-13 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
EP2482078B1 (en) | 2006-05-01 | 2016-02-03 | Critical Care Diagnostics, Inc. | Diagnosis of cardiovascular disease |
HUE025058T2 (en) | 2006-05-02 | 2016-01-28 | Critical Care Diagnostics Inc | Differential diagnosis of pulmonary and cardiovascular disease |
RU2355295C1 (ru) | 2007-10-23 | 2009-05-20 | Федеральное Государственное Учреждение "Саратовский Научно-Исследовательский Институт Кардиологии Росмедтехнологий" | Способ реабилитации больных ибс |
EP3093663B1 (en) | 2008-04-18 | 2018-06-13 | Critical Care Diagnostics, Inc. | Predicting risk of major adverse cardiac events |
GB0818650D0 (en) * | 2008-10-10 | 2008-11-19 | Uni I Oslo | Methods |
JP5584695B2 (ja) * | 2008-11-11 | 2014-09-03 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Adm及びbnpのレベルを決定することによる心疾患に罹患した患者の予後診断及びリスク評価 |
EP2556090B1 (en) | 2010-04-09 | 2016-02-24 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
CN106940375B (zh) | 2011-03-17 | 2019-03-08 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
DK2734222T3 (en) | 2011-07-18 | 2017-01-30 | Critical Care Diagnostics Inc | PROCEDURES FOR TREATING CARDIOVASCULAR DISEASES AND PREDICTING THE EFFECTIVENESS OF MOTION THERAPY |
RU2603471C2 (ru) | 2012-01-04 | 2016-11-27 | УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения |
EP3434260A1 (en) | 2012-05-18 | 2019-01-30 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of ventricular tachyarrhythmia event |
WO2014028875A1 (en) | 2012-08-16 | 2014-02-20 | Critical Care Diagnostics, Inc. | Methods for predicting risk of developing hypertension |
SG11201501271TA (en) | 2012-08-21 | 2015-03-30 | Critical Care Diagnostics Inc | Multimarker risk stratification |
CA2935958A1 (en) | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2012
- 2012-07-18 DK DK12814331.0T patent/DK2734222T3/en active
- 2012-07-18 MX MX2014000715A patent/MX351428B/es active IP Right Grant
- 2012-07-18 EP EP12814331.0A patent/EP2734222B1/en not_active Not-in-force
- 2012-07-18 BR BR112014001283A patent/BR112014001283A2/pt not_active Application Discontinuation
- 2012-07-18 ES ES12814331.0T patent/ES2611403T3/es active Active
- 2012-07-18 EP EP16192678.7A patent/EP3173093B1/en not_active Not-in-force
- 2012-07-18 PL PL12814331T patent/PL2734222T3/pl unknown
- 2012-07-18 CN CN201280045405.6A patent/CN103796669B/zh not_active Expired - Fee Related
- 2012-07-18 US US13/552,533 patent/US8748110B2/en not_active Expired - Fee Related
- 2012-07-18 AU AU2012284039A patent/AU2012284039B2/en not_active Ceased
- 2012-07-18 CN CN201610902184.XA patent/CN106908604B/zh active Active
- 2012-07-18 CA CA2842072A patent/CA2842072A1/en not_active Abandoned
- 2012-07-18 WO PCT/US2012/047238 patent/WO2013012945A1/en active Application Filing
- 2012-07-18 JP JP2014521739A patent/JP6134316B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-09 US US14/299,851 patent/US9551708B2/en active Active
- 2014-11-18 HK HK14111635.2A patent/HK1198125A1/xx not_active IP Right Cessation
-
2017
- 2017-01-18 US US15/409,283 patent/US20170122942A1/en not_active Abandoned
- 2017-04-21 JP JP2017084084A patent/JP6416974B2/ja not_active Expired - Fee Related
- 2017-06-23 AU AU2017204261A patent/AU2017204261B2/en not_active Ceased
-
2018
- 2018-10-25 US US16/170,870 patent/US10928393B2/en active Active
-
2021
- 2021-02-04 US US17/167,246 patent/US20210164976A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014001283A2 (pt) | métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício | |
MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
BR112014017626A2 (pt) | métodos para tratar uma doença ou disfunção, métodos de identificação de um indivíduo, método para prever se um indivíduo com uma doença ou disfunção tem mais ou menos probabilidade para desenvolver toxicidade ao tratamento, método para determinar se um indivíduo com uma doença ou disfunção deve continuar ou suspender o tratamento que compreende um modulador de fgf19, método de otimização de eficácia terapêutica e método de ensaio | |
BR112012022801A2 (pt) | métodos de diagnosticar e tratar câncer em pacientes que têm ou que desenvolvem resistência a uma primeira terapia contra o câncer. | |
AR084831A1 (es) | Terapia anticancer mediante inhibidores de quinasa | |
MX2019002996A (es) | Nanopartículas como sustratos catalíticos para biodetección en tiempo real del desempeño humano y diagnóstico y métodos terapéuticos. | |
BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
SG195191A1 (en) | Methods and compositions of predicting activity of retinoid x receptor modulator | |
BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
BR112014000380A2 (pt) | composição farmacêutica, métodos para tratamento e usos dos mesmos | |
BR112013031032A2 (pt) | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos | |
BR112014024219A8 (pt) | Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit | |
BR112014020233A2 (pt) | seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43 | |
BR112014013924A8 (pt) | métodos para tratar distúrbios cardiovasculares | |
MX2016016139A (es) | Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5. | |
MX352680B (es) | Metodos y productos para el diagnostico in vitro, pronosticos in vitro y desarrollo de farmacos contra carcinomas invasivos. | |
BRPI0920170A2 (pt) | métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método. | |
MX2010010799A (es) | Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea. | |
MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
BR112015000685A2 (pt) | método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza. | |
JP2016533388A5 (pt) | ||
EP4241677A3 (en) | System for predictive neurodevelopment therapy for oral feeding | |
WO2015036643A3 (es) | Marcador para predecir metástasis del cáncer de mama | |
Reid | Prevention of osteoporosis after breast cancer | |
WO2015067710A3 (en) | Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |